Replies to post #107110 on Biotech Values

[DewDiligence]

what type of figures are you forecasting in terms of market share [for generic Lovenox] over the next 1-2 quarters?

45-50% of dollar sales, i.e. no major change from NVS’ current share.

do you still believe TEVA won't receive approval for a substantial amount of time (greater than 6 months)?

I do not expect Teva to obtain FDA approval for generic Lovenox ever.